Jpmorgan Chase & CO Homology Medicines, Inc. Transaction History

Jpmorgan Chase & CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$0.83 - $1.12 $342,267 - $461,855	-412,371 Reduced 99.77%	954 $0
Q4 2022 Feb 13, 2023	SELL	$1.09 - $2.04 $2,534 - $4,743	-2,325 Reduced 0.56%	413,325 $521,000
Q3 2022 Nov 14, 2022	SELL	$1.55 - $3.01 $456,174 - $885,861	-294,306 Reduced 41.45%	415,650 $669,000
Q2 2022 Aug 11, 2022	SELL	$1.39 - $3.12 $31,793 - $71,363	-22,873 Reduced 3.12%	709,956 $1.4 Million
Q1 2022 May 11, 2022	SELL	$2.6 - $4.17 $141,515 - $226,968	-54,429 Reduced 6.91%	732,829 $2.23 Million

Q4 2021 Feb 10, 2022	SELL	$3.64 - $7.78 $1.34 Million - $2.87 Million	-369,440 Reduced 31.94%	787,258 $2.87 Million
Q3 2021 Nov 12, 2021	BUY	$6.01 - $8.71 $6.95 Million - $10.1 Million	1,156,698 New	1,156,698 $9.1 Million

66.2K

Ticker FIXX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 57,402,000
Description
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nucleas...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.